NEW YORK, NY / ACCESS Newswire / April 11, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want ...

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSE:ATNM – Free Report) from a sell rating to a hold rating in a ...

Law Offices of Howard G. Smith announces an investigation on behalf of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) investors concerning the Company ...

Actimab-A is a novel targeted radiotherapeutic that uses the Actinium-225 (Ac-225) isotope payload directed against CD33, a marker expressed ubiquitously on AML blasts. The trial was conducted at ...

- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA ® or OPDIVO ® can result in improved patient outcomes - MDSCs – Myeloid Derived Suppressor Cells in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting - Actinium is ...

Actinium Pharma inks supply agreement with Eckert & Ziegler for Ac-225 radioisotope to support comprehensive development activities: New York Wednesday, March 26, 2025, 18:00 Hrs ...

Actinium's Chairman and CEO, said, "The current era of radiotherapy is built on the clinical and commercial success of Pluvicto in prostate cancer. The field is now looking to address patients ...

Actinium Pharma inks research pact with Memorial Sloan Kettering to support further clinical expansion of Actimab-A's backbone therapy strategy: New York Saturday, March 22, 2025, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...